Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

Apr. 22, 2025 — Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration— BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Pope Francis passed away at 88 in Rome on Easter Monday after a prolonged illness. The Vatican reported the cause of death as a stroke leading to coma ...

Incorporated announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic ...

At the moment, no specific diet is officially recommended for lung health. But in a 2024 study published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, Jackson and ...

Bronchitis is a condition in which the airways in your lungs, called the Trachea and the Bronchi, get inflamed and fill with ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators ...